logo
Share SHARE
FONT-SIZE Plus   Neg

CHMP Adopts Negative Opinion On KYNAMROTM - Quick Facts

Genzyme, a Sanofi company (SNY), and Isis Pharmaceuticals Inc. (ISIS), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.

An application for KYNAMRO is currently under review by the U.S. FDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Discount retailer Five Below Inc (FIVE), Wednesday said its first-quarter profit increased from a year ago, driven largely by a 22 percent jump in sales, with both earnings and revenues coming in ahead of Wall Street estimates. Five Below detailed a strong outlook for the second quarter and lifted... Yahoo Inc has won exclusive rights to the National Football League's first Internet-only broadcast of a football game between the Buffalo Bills and Jacksonville Jaguars that will be played in London on Sunday, October 25. Applications for home mortgages in the U.S. declined last week on a seasonally adjusted basis as purchase and refinancing applications waned, shows data by the Mortgage Bankers Association.
comments powered by Disqus
Follow RTT